Allarity Therapeutics Inc. has filed a new prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $10 million to $18 million. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company plans to offer and sell its common stock through Ascendiant Capital Markets, LLC, acting as the Sales Agent, under the terms of the At-The-Market Issuance Sales Agreement. As of March 6, 2024, the aggregate market value of Allarity's common stock held by non-affiliates was approximately $55.1 million, with the company having already sold $12.9 million worth of stock in the past 12 months. The company is eligible to sell an additional $5.4 million of common stock, ensuring that the total...Show More

Allarity Therapeutics Inc. has filed a new prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $10 million to $18 million. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company plans to offer and sell its common stock through Ascendiant Capital Markets, LLC, acting as the Sales Agent, under the terms of the At-The-Market Issuance Sales Agreement. As of March 6, 2024, the aggregate market value of Allarity's common stock held by non-affiliates was approximately $55.1 million, with the company having already sold $12.9 million worth of stock in the past 12 months. The company is eligible to sell an additional $5.4 million of common stock, ensuring that the total does not exceed one-third of the aggregate market value of the stock held by non-affiliates within any 12-month period, as per General Instruction I.B.6 of Form S-3. The company cautions that investing in its common stock involves a high degree of risk, as detailed in the risk factors section of the prospectus supplement dated March 19, 2024.